Primary prophylactic effect of PEG-rhG-CSF in head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048522

Enrollment

Unknown

Registered

2021-07-09

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell carcinoma of head and neck

Interventions

Experimental Group:PEG-rhG-CSF was administered 24-48 hours after concurrent chemoradiotherapy

Control Group:No

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Head and neck squamous cell carcinoma patients aged 18 to 70 years; 2. Those who need concurrent chemoradiotherapy; 3. Karnofsky score>=70, white blood cell>=3.5x10^9/L, platelet>=100x10^9/L, hemoglobin>=100g/L, normal liver and kidney function; 4. Agree to join the group and sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. People with drug allergies; 2. One-week chemotherapy regimens for patients.

Design outcomes

Primary

Measure	Time frame
cell blood count;	—

Secondary

Measure	Time frame
Oral Mucositis;	—

Countries

China

Contacts

Public ContactDu Guobo

Affiliated Hospital of North Sichuan Medical College

duguobo@yeah.net+86 13890800046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026